HEALTHCARE ROYALTY PARTNERS β Full Portfolio
79 tracked investments Β· listed companies and verified rows first
Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.
BiotechHealthtechLexington, US
Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in
Co-investorsAdvent Life SciencesGrazia Equity GmbHOberland CapitalCommodore CapitalInvusLigand Pharmaceuticals+1 more
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.
BiotechDigital HealthHealthtechCambridge, US
Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)inBarry Wohl(Chief Business Officer)inKetan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)
Co-investorsAlpha Wave GlobalMorningside GroupSectoral Asset Management
Aptevo Therapeutics is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies to treat cancer.
BiotechHealthtechSeattle, US
Marvin L White(Executive Officer, Director)inJeffrey G Lamothe(Executive Officer, Director)Daphne Taylor(Executive Officer)
BoardJohn E Niederhuber(Director)Daniel J Abdun-Nabi(Director)Grady Grant III(Director)
Co-investorsYorkville Advisors
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.
BiotechHealthtechMedical DevicesThousand Oaks, US
AnhCo Nguyen(President and Chief Executive Officer)
Co-investorsDag VenturesEcoR1 CapitalKleiner PerkinsDomain AssociatesFidelity Investments
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.
BiotechHealthtechMedical DevicesRedwood City, US
Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)
Co-investorsF-Prime CapitalSofinnova VenturesVenrock
Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction.
BiotechHealthtechSan Francisco, US
Howard W. Robin(Executive Officer, Director)Gil M. Labrucherie(Executive Officer)inManinder Hora(Executive Officer)inStephen K. Doberstein(Executive Officer)John Nicholson(Executive Officer)Jillian B. Thomsen(Executive Officer)
Co-investorsNew Enterprise Associates (NEA)
BiotechTel Aviv
Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)
Co-investorsLifeSci Venture Partners
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)Vikas Goyal(Director)
Co-investorsMRL Ventures FundOUP (Osage University Partners)RA CapitalAlphabetAtlas VentureFidelity Investments
BiotechIrvine, US
Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)
BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)
Co-investorsEvidity Health CapitalFlying L PartnersSV Life SciencesVersant Venture AIV HoldingsVersant Ventures
The site presents ADYNOVATE, a PEGylated recombinant antihemophilic Factor VIII injectable used to treat and control bleeding in adults and children with hemophilia A.
BiotechHealthtech
A biopharmaceutical company (Ipsen, following its acquisition of Albireo Pharma) developing and commercializing medicines in oncology, rare diseases, and neuroscience for patients with high unmet medical needs.
BiotechHealthtech
Co-investorsDecheng Capital
Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.
BiotechFremont, US
Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)inDavid Rosenbaum(Executive Officer)inJeremy Caldwell(Executive Officer)Mike Raab(Executive Officer, Director)in
BoardDavid Mott(Director)
Co-investorsForesite CapitalNew Enterprise Associates (NEA)
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesLongwood FundSequoia Capital
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)Todd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Co-investorsSofinnova VenturesMPM BioImpact
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.
BiotechHealthtechMedical DevicesAlpharetta, US
Mark Prausnitz(Director)inCharles Deignan(Executive Officer)Glenn Noronha(Executive Officer)inDaniel H. White(Executive Officer, Director)in
BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in
Co-investorsMountain Group CapitalSolasta VenturesHatterasHatteras Venture Partners
EBVALLO is an on-demand allogeneic T-cell immunotherapy for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.
BiotechDigital HealthMedical Devices
ELIGARD is a GnRH agonist medication in injectable form used to treat prostate cancer by reducing testosterone production.
BiotechHealthtechMedical Devices
IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used either in combination with ursodeoxycholic acid or as a standalone treatment for patients unable to tolerate standard therapy.
BiotechHealthtechMedical Devices
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(Executive Officer, Director)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsAvoro Capital AdvisorsForesite CapitalRA Capital
KORSUVA is a prescription medicine that treats moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis.
BiotechDigital HealthHealthtechMedical Devices
Lantheus is a radiopharmaceutical company that develops, manufactures, and commercializes radiodiagnostics and radiotherapeutics for cancer detection, treatment and monitoring, as well as precision diagnostics for non-oncologic diseases.
BiotechHealthtechMedical DevicesNorth Billerica, US
Lyrica is a pharmaceutical product used to manage fibromyalgia, a chronic condition characterized by widespread pain and fatigue.
BiotechHealthtechMedical Devices
Nanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients.
BiotechDeep TechMedical Devices
OPKO Health is a fully integrated healthcare company developing multispecific therapies for serious diseases including cancers and infectious diseases, and operates BioReference Laboratories, a clinical reference laboratory serving approximately 11 million patients annually in the U.S.
BiotechDigital HealthHealthtechMedical DevicesMiami, US
Gary Nabelin
Orenitram is a prescription oral medication containing treprostinil, indicated to treat pulmonary arterial hypertension (PAH) by slowing disease progression and improving exercise capacity in adults.
BiotechHealthtech
Progenics Pharmaceuticals was a Tarrytown, NY-based oncology biopharmaceutical company developing targeted cancer therapeutics and diagnostic imaging agents, including PSMA-targeted prostate cancer products and AZEDRA.
Co-investorsSofinnova Ventures
REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies.
BiotechHealthtechRockville, US
Kenneth T. Mills(Executive Officer, Director)
BoardJohn Daniel Kiser(Director)Allan M. Fox(Director)Benjamin Auspitz(Director)Donald J. Hayden, Jr.(Director)
Co-investorsF-Prime CapitalVenrock
RELISTOR is a prescription medication containing methylnaltrexone bromide that treats opioid-induced constipation in adults with chronic pain or advanced illness.
BiotechDigital HealthHealthtechMedical Devices
Relypsa was a biopharmaceutical company that developed non-absorbed polymeric drugs, including Veltassa, a potassium-binding agent for treating hyperkalemia in cardiovascular and renal disease patients.
Co-investors5AM Ventures
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)in
Co-investorsForesite CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMedThird Rock Ventures
SEYSARA is a prescription medication with a patient co-pay assistance program (Almirall Advantage) that offers savings on retail and network pharmacy purchases.
BiotechHealthtech
Morrisville, US
Manoj George(Executive Officer)Joe Boorady(Executive Officer, Director)
BoardJoe Mandato(Director)Immanuel Thangaraj(Director)Abhijeet Lele(Director)Todd Davis(Director)
IBSRELA is a prescription medication containing tenapanor designed to treat irritable bowel syndrome with constipation (IBS-C) in adults by reducing constipation and abdominal pain.
BiotechHealthtechMedical Devices
TG Therapeutics is a biopharmaceutical company focused on developing treatments for cancer patients.
BiotechHealthtechMedical Devices
Michael S. Weiss(CEO)
Theravance Biopharma develops FDA-approved pharmaceutical treatments, including YUPELRI for chronic obstructive pulmonary disease (COPD) maintenance treatment.
BiotechHealthtechMedical Devices
Rick E Winningham(Chief Executive Officer)inRhonda F. Farnum(Senior Vice President, Commercial and Medical Affairs and Chief Business Officer)inBrett A. Grimaud(Senior Vice President, General Counsel and Secretary)inStuart Knight(Senior Vice President, IT&I and Chief Information Officer)Aine Miller(Senior Vice President, Development and Head of Ireland Office)Stacy Pryce(Senior Vice President and Chief Strategy Officer)in
TRELEGY is a once-daily prescription inhaler used long-term to treat COPD (including chronic bronchitis and emphysema) and asthma in adults.
Biotech
uniQure is a biotech company developing gene therapies for serious genetic diseases.
BiotechHealthtechMedical Devices
Matthew Kapustain
Co-investorsAdvent Life SciencesForesite Capital
Vafseo (vadadustat) is a once-daily oral prescription medicine that treats anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months.
BiotechHealthtech
ZOLGENSMA is a gene replacement therapy that delivers a working SMN gene to treat spinal muscular atrophy (SMA), a rare genetic disease affecting motor nerve cells.
BiotechDigital HealthHealthtechMedical Devices
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.